Ascentage Pharma Group International (HKSE:06855) 3-Year Revenue Growth Rate : 195.70% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International 3-Year Revenue Growth Rate?

Ascentage Pharma Group International's Revenue per Share for the six months ended in Dec. 2024 was HK$0.54.

During the past 12 months, Ascentage Pharma Group International's average Revenue per Share Growth Rate was 303.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 195.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 107.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Ascentage Pharma Group International was 195.70% per year. The lowest was 23.60% per year. And the median was 69.80% per year.

Competitive Comparison of Ascentage Pharma Group International's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Ascentage Pharma Group International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Ascentage Pharma Group International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Ascentage Pharma Group International (HKSE:06855) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Ascentage Pharma Group International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

AAPG:USA 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Takeda Pharmaceuticals International Ag	2101 Beneficial owner
Takeda Pharmaceuticals Company Limited	2201 Interest of corporation controlled by you
Gao Sharon Xia
Zhai Yifan
Yang Dajun
Wang Shaomeng
Li Ju-yun
Healthquest Pharma Limited
Guo Edward Ming
Ascentage Limited
South Dakota Trust Company Llc	2301 Trustee
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines